Cystitis during menopause: causes and treatment

Cystitis is more common during menopause due to hormonal and microbiological changes in the urogenital tract. Estrogen deficiency leads to increased vaginal pH, decreased lactobacilli, and decreased local immunity, facilitating colonization by uropathogens, primarily E. coli. These changes are often associated with genitourinary syndrome of menopause, which can mimic or exacerbate the symptoms of cystitis. [1]

It is important to distinguish between acute uncomplicated cystitis, recurrent cystitis, and asymptomatic bacteriuria. Treatment of asymptomatic bacteriuria in non-pregnant postmenopausal women is not recommended, as therapy does not improve outcomes and increases the risk of resistance. This approach is supported by major European guidelines.

Leading modern guidelines recommend diagnosing acute cystitis in women with typical complaints primarily clinically. Routine urine culture is not mandatory in uncomplicated cases, but is necessary in cases of atypical progression, treatment failure, or relapse. This avoids overprescribing antibiotics and allows for focused therapy. [2]

Relapse prevention deserves special attention. The role of topical estrogen therapy in postmenopausal women has been proven, and the evidence base for methenamine hippurate is growing. For some supplements, such as D-mannose, the data are conflicting. [3]

Why does menopause increase the risk of cystitis?

Following ovarian failure, estrogen receptor expression in the urethra, trigone, and vagina decreases, the epithelium thins, glycogen levels decrease, and Lactobacillus numbers decline. This increases pH and disrupts colonization resistance, facilitating the attachment and invasion of uropathogens in the lower urinary tract. [4]

Genitourinary syndrome of menopause manifests as dryness, burning, dyspareunia, and dysuria. Some urological symptoms associated with estrogen deficiency are not caused by infection, but by atrophic changes in the mucous membranes, which is important to consider when choosing therapy. Local estrogen therapy restores lactobacilli and lowers pH, reducing the risk of infection. [5]

Additional factors include decreased circulating fluid volume, more frequent episodes of residual urine due to pelvic floor dysfunction, comorbidities, and the use of medications with anticholinergic effects. This combination of factors creates a favorable "ecology" for relapse. [6]

Finally, some patients have asymptomatic bacteriuria, for which treatment is not indicated. The absence of symptoms of burning and frequent urination despite the presence of bacteria in the urine often indicates colonization rather than infection, and antibacterial therapy in this situation is harmful.

Symptoms and how to distinguish them from genitourinary syndrome of menopause

Classic signs of acute cystitis include frequent urination in small amounts, an urgent urge to urinate, cramping and pain in the lower abdomen, and sometimes microhematuria. Systemic intoxication and fever are uncommon and suggest pyelonephritis. During menopause, some symptoms may overlap with those of atrophic vaginitis. [7]

Genitourinary syndrome of menopause causes dryness, burning, painful intercourse, and discomfort in the urethra and vagina, sometimes mimicking an infection. A distinctive feature of cystitis remains its acute onset with pronounced dysuric symptoms, while with genitourinary syndrome (GUS), symptoms are more chronic and intermittent. [8]

Postmenopausal women often experience a mixed picture: a true infection accompanied by a DBS infection. In this case, in addition to the etiotropic treatment, local estrogen therapy is considered, which reduces the likelihood of further episodes. This strategy is included in the recommendations.

If there is discharge, severe itching, or an unpleasant odor, a vaginal pathology is likely. If pelvic pain occurs without bacteriuria and cultures are negative, bladder pain syndrome should be considered. Proper differentiation saves antibiotics and speeds recovery. [9]

Table 1. How to distinguish cystitis from genitourinary syndrome of menopause

Sign	Acute cystitis	Genitourinary syndrome of menopause
Start	A sharp debut	Gradually, chronically
Main complaints	Burning, frequent urge, pain when urinating	Dryness, burning, dyspareunia, urethral discomfort
Fever	Usually absent	Absent
Urine culture	Often positive	Mostly negative
Tactics	Short-course antimicrobial therapy	Topical estrogens, moisturizers, and treatment of infection if necessary

When to urgently see a doctor

Immediate evaluation is necessary for fever, chills, flank pain, nausea, vomiting, severe weakness, urinary retention, and anuria. These signs may indicate upper urinary tract involvement or a complicated course requiring a different approach. [10]

Severe hematuria, relapses more than 3 episodes per year, suspicion of urolithiasis, neurogenic bladder, cystitis due to immunodeficiency, recent urological interventions are reasons for extended diagnostics. [11]

If symptoms persist for more than 72 hours despite adequate empirical therapy or recur within 2 weeks, urine culture with sensitivity testing and treatment adjustment are necessary. This reduces the risk of resistance and complications. [12]

In elderly and fragile patients, atypical progression is more common. Early laboratory confirmation and assessment of risk factors for systemic progression are helpful. [13]

Table 2. Red flags for cystitis during menopause

Sign	Possible problem	Action
Fever, pain in the side	Pyelonephritis	Seek immediate medical attention
Urinary retention	Lower tract obstruction	Urgent Care
Severe hematuria	Stone, tumor, severe inflammation	Urgent diagnostics
No effect for 72 hours	Resistance or misdiagnosis	Sowing, change of therapy
Relapses ≥3 per year	Recurrent cystitis	Prevention plan and in-depth examination

Diagnostics

Step 1. Clinical assessment of typical symptoms. In a typical uncomplicated course, the diagnosis is probable and immediate empirical therapy without culture is possible. [14]

Step 2. A dipstick test and a general urine analysis increase the likelihood of diagnosis, but their sensitivity and specificity are limited. Positive nitrites and leukocyte esterase support the diagnosis, but a negative test does not rule out infection in severe symptomatic patients. [15]

Step 3. Urine culture is indicated for atypical symptoms, lack of improvement, relapses, pregnancy, and suspected complications. The threshold for significant bacteriuria with typical symptoms may be lower than the classical threshold, which is taken into account during interpretation. [16]

Step 4. Rule out asymptomatic bacteriuria and vaginal causes. In the absence of complaints, treatment for urinary bacteria in postmenopausal women is not required. If signs of GBS are present, urological and gynecological approaches are combined. [17]

Table 3. Diagnostic tactics for suspected cystitis during menopause

Situation	Urgent actions	Laboratory	Is sowing necessary?
Classic symptoms, no red flags	Empirical therapy	Urine analysis if possible	Not required
Atypical symptoms or no effect within 72 hours	Clarifying the diagnosis	Urine analysis	Required
Relapses	Prevention plan	Urine analysis	Desirable
Suspected fuel and lubricants	Gynecological evaluation	-	No
Asymptomatic bacteriuria	Observation	-	There is no treatment

Differential diagnosis

Acute cystitis should be distinguished from vaginitis, sexually transmitted infections, bladder pain syndrome, and overactive bladder. These conditions can cause dysuria and frequent urination without bacterial growth in culture. [18]

Severe discharge and itching suggest vaginitis, while pelvic pain and negative cultures suggest bladder pain syndrome. The absence of nocturnal polyuria and cramping is more typical of urinary tract infection than of an infection. Treatment depends directly on a proper diagnosis. [19]

Concomitant conditions are taken into account: stones, pelvic organ prolapse, residual urine, neurogenic disorders. These factors increase the risk of complications and relapses. [20]

Regular review of the diagnosis is necessary in case of atypical course and frequent relapses, since some cases require urological examination and correction of risk factors. [21]

Table 4. What mimics cystitis in menopausal women

State	Tips	Approach
Genitourinary syndrome of menopause	Chronic dryness, dyspareunia	Local estrogens, moisturizers
Vaginitis	Itching, discharge, odor	Smears, targeted treatment
Bladder pain syndrome	Chronic pelvic pain, negative cultures	Behavioral and specialized therapy
Overactive bladder	Urgent urges without infection	Behavioral and drug therapy
Urolithiasis	Pain, hematuria	Visualization, urological tactics

Treatment of acute uncomplicated cystitis

First-line antibacterial therapy in women includes fosfomycin trometamol 3 g once daily, nitrofurantoin 100 mg twice daily for 5 days, or pivmecillinam 400 mg three times daily for 3-5 days. These regimens have shown high efficacy and a low risk of systemic side effects. Fluoroquinolones and aminopenicillins are not recommended for the treatment of cystitis. [22]

If symptoms persist for more than 72 hours after treatment, urine culture and sensitivity testing are necessary, and the drug should be changed. This reduces the risk of persistent infection and repeated treatment failure. [23]

Considering age and comorbidities, it is important to assess tolerability and interactions. If pyelonephritis, systemic manifestations, or complicating factors are suspected, empirical treatment and tactics differ and require immediate medical attention. [24]

Irrational use of antibiotics increases resistance, so long courses without indications and "just in case" therapy are unacceptable. Focusing on short, effective regimens is a key strategy. [25]

Table 5. First-line therapy for acute cystitis in women

Preparation	Dose	Duration	Notes
Fosfomycin trometamol	3 g once	Day 1	The drug of choice for many patients
Nitrofurantoin	100 mg 2 times a day	5 days	Effective in low risk of pyelonephritis
Pivmecillinam	400 mg 3 times a day	3-5 days	First line in a number of countries
Oral cephalosporins	Comparable modes	3 days	Alternative
Trimethoprim sulfamethoxazole	160 mg with 800 mg 2 times a day	3 days	If local resistance is low

Recurrent cystitis: how to prevent new episodes

Local estrogen therapy in postmenopausal women reduces the recurrence rate by restoring vaginal microbiota and pH. This effect has been confirmed in meta-analyses and is included in strong recommendations of European guidelines. The drugs are administered rectovaginally in low doses, with minimal systemic exposure. [26]

Methenamine hippurate is a non-antibiotic antiseptic that forms formaldehyde in acidic urine and inhibits bacterial growth. In a multicenter, randomized trial, it was found to be as effective as long-term antibiotic prophylaxis in women with recurrent urinary tract infections, making it a valuable tool for antimicrobial stewardship. Guidelines recommend it for women without urinary tract abnormalities. [27]

Cranberry products show a moderately significant reduction in the risk of symptomatic relapses in women with recurrent episodes. The effect varies across groups, and the optimal dose of proanthocyanidins has not been determined, but an updated review confirms benefits in a range of populations. [28]

There is conflicting evidence for D-mannose. A recent randomized trial showed no statistically significant reduction in the proportion of women with a recurrent episode within 6 months, and European guidelines emphasize weak and inconsistent evidence. Patients should be informed of this when co-selecting a strategy. [29]

Table 6. Relapse prevention

Approach	Evidence	Who is it suitable for?	Comments
Local estrogens	High	Postmenopause with GSM	Reduce relapses and restore microbiota
Methenamine hippurate	High	Women without urinary tract anomalies	An alternative to long-term antibiotics
Cranberry products	Moderate	Women with relapses	Variability of drugs and doses
D-mannose	Conflicting data	Consider individually	Report weak evidence
Low dose antibiotics	Effective, but with risks	If other measures are ineffective	Minimize duration and risk of resistance

Lifestyle and behavioral measures

Adequate fluid intake and regular urination reduce the time bacteria are in contact with the mucous membrane and may reduce the frequency of episodes. It is important to avoid urinary retention and constipation, which increase intra-abdominal pressure and impair bowel movements. [30]

Genital hygiene with gentle products without harsh surfactants helps maintain the barrier. Avoiding spermicides and diaphragms and choosing alternative contraception reduces the risk of recurrence. [31]

For postcoital episodes, post-coital urination and, if indicated, postcoital prophylaxis are discussed. For many patients, behavioral measures combined with topical estrogens are sufficient. [32]

Patients with uterine dysfunction benefit from vaginal moisturizers and lubricants that reduce mechanical irritation of the urethra, as well as regular use of prescribed estrogens to maintain the effect. [33]

Table 7. Everyday steps that really help

Measure	How it works	Comment
Drinking regimen	Dilutes urine and increases diuresis	Individually, taking into account the heart and kidneys
Regular bowel movements	Reduces contact time with the uroepithelium	Avoid delays
Intimate care	Maintains barrier and pH	Without aggressive means
Avoiding spermicides	Reduces irritation and dysbiosis	Discuss alternatives
Moisturizers and lubricants	Reduce friction and microtrauma	Supplement local estrogens

Frequently asked questions

Should bacteria in urine be treated if there are no symptoms?
In non-pregnant postmenopausal women, no. Exceptions include preparation for invasive procedures and pregnancy.

Are topical estrogens dangerous?
Low-dose vaginal therapy provides minimal systemic exposure and effectively reduces urogenital symptoms, reducing the risk of recurrence. The decision should be made in consultation with a physician, especially if there is a history of cancer. [34]

Is it possible to avoid antibiotics during relapses?
Yes, for some patients, topical estrogens, methenamine hippurate, and behavioral interventions are appropriate. Antibiotics are reserved for situations when other strategies fail.

Should I take cranberry and D-mannose?
Cranberry products modestly reduce the risk of relapse in some women, but the data on D-mannose are conflicting. Weigh the benefits against the cost and understand the limitations of the evidence. [35]

Conclusions

Cystitis during menopause is a common and manageable problem. The guiding principles are clinical diagnosis based on typical symptoms, short and effective treatment regimens, avoiding treatment for asymptomatic bacteriuria, and reducing recurrence using topical estrogens, methenamine hippurate, and sensible behavioral measures. This approach increases efficacy and reduces the risk of antibiotic resistance. [36]